• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Life Sciences | News, Analysis, Insights - HIT Consultant

7 Burning Questions from Life Sciences Companies on Using AI Agents

by Troy Lase, Associate Director, Commercial Strategic Planning, IQVIA and Richard Marcil, Chief Customer Officer, ConversationHEALTH 01/19/2022 Leave a Comment

7 Burning Questions from Life Sciences Companies on Using AI Agents

Each day life science companies respond to numerous medical information inquires – many of which are similar in nature or can be simply addressed. However, as we have seen in the news reports with the Great Resignation and many workers searching for new careers, the number of individuals interested in working in a medical information contact center may be waning. When you combine this with the rising volume of inquiries or medical inquiries and patient expectations for a real-time response to
Read More

Spatial Omics: The Next Wave in the Biological Research Revolution

by Josh Ryu, Chief Technology Officer and Co-founder, Rebus Biosystems 01/19/2022 Leave a Comment

Spatial Omics: Seeing the Forest Through the Trees

For decades, biomedical researchers pursued a reductionist strategy, investigating DNA, RNA, proteins and other cellular players in isolation. These studies have been critically important, providing vital parts lists to guide further exploration. Now, however, biology has entered a new age, in which scientists must adopt more contextual approaches to understand the fundamental units of life – cells.  But to truly understand how cells operate, we must explore their relationships in time
Read More

Truepill Launches COVID-19 Test Coverage Platform

by Jasmine Pennic 01/18/2022 Leave a Comment

Truepill Launches COVID-19 Test Coverage Platform

What You Should Know: - Truepill, the digital health platform connecting telehealth, diagnostics, and pharmacy to transform consumer healthcare launches COVID-19 Test Coverage Platform, adding to its growing suite of COVID-19 solutions. The COVID-19 Test Coverage Platform is the latest tool in Truepill’s suite of COVID-19 wellness solutions, which includes an end-to-end COVID-19 testing platform and a COVID-19 virtual care platform that provides on-demand telehealth consults and
Read More

iSpecimen Expands COVID-19 Research with Sequences Specimens to Detect Variants

by HITC Staff 01/14/2022 Leave a Comment

iSpecimen Expands COVID-19 Research with Sequences Specimens to Detect Variants

What You Should Know: - iSpecimen, the developer of an online marketplace that connects human biospecimen with researchers, announced that is has expanded its supplier capabilities in support of COVID-19 researchers. - Through a new partnership with a reference lab in New York, researchers looking to validate their own COVID variant identification assays can obtain sequenced and unsequenced COVID-19 positive and negative swabs in a variety of media types through iSpecimen. This lab is
Read More

Decentralized Clinical Trials Can Achieve Net Financial Benefits of 5X to 14X

by Fred Pennic 01/13/2022 Leave a Comment

3 Barriers to Decentralized Clinical Trials Adoption

What You Should Know: - New data from Tufts and Medable reveal on average, decentralized clinical trials (DCTs) are associated with reduced clinical trial timelines and can achieve net financial benefits ranging from five to 14 times for Phase II and Phase III trials, respectively.  - The findings are based on financial modeling and analysis of trial data from the Tufts Center for the Study of Drug Development (CSDD), Tufts University School of Medicine, and more than 150 clinical trials
Read More

GSK Launches Accelerated Clinical Trial with Tempus

by Jasmine Pennic 01/13/2022 Leave a Comment

Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative to Advance Precision Cancer Treatment

What You Should Know: - Tempus and GlaxoSmithKline (GSK) announced an accelerated phase II study evaluating the efficacy and safety of niraparib, an oral, once daily PARP inhibitor, for patients with breast and pancreatic cancers. The study, titled “Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors” (the PAVO study, NCT05169437) is sponsored by Tempus and opened for enrollment on January 7, 2022. - This trial’s data-driven design and site selection
Read More

Sanofi Taps BrightInsight for Development of Software as a Medical Device

by Fred Pennic 01/13/2022 Leave a Comment

Sanofi, TriNetX Partner to Optimize Clinical Trials with Digital Technology

What You Should Know: - Sanofi, a global biopharmaceutical company focused on human health has inked a strategic partnership with  BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solution to bring to market a next-generation digital companion application for one of Sanofi’s products. - The BrightInsight® Platform has been selected to serve as the underlying infrastructure to accelerate continuous development of one of Sanofi’s
Read More

PostEra Secures $24M, Forms $260M AI Lab Collaboration with Pfizer

by Fred Pennic 01/11/2022 Leave a Comment

PostEra Secures $24M, Forms $260M AI Lab Collaboration with Pfizer

What You Should Know: - PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients. - PostEra will use the proceeds to advance a series of partnered drug discovery programs, initiate its own internal drug discovery, and further develop its medicinal chemistry platform. True to its collaborative ethos, the company today also announced its
Read More

Verily, Sosei Heptares Collaborate to Generate Novel Drug Candidates Against GPCR Targets for Immune-Mediated Diseases

by Jasmine Pennic 01/06/2022 Leave a Comment

Verily, Sosei Heptares Collaborate to Generate Novel Drug Candidates Against GPCR Targets for Immune-Mediated Diseases

What You Should Know: - Verily and Sosei Heptares announced a new research collaboration combining Verily’s Immune Profiler platform, a next gen immune mapping platform, with Sosei Heptares’ world-leading StaR (stabilized receptor) platform, with the goal of rapidly identifying novel drug candidates across multiple immune-based disorders. - Together, the collaboration will focus on accelerating the development of new drug candidates against
Read More

Protai Nabs $8M for AI-Powered Drug Discovery Platform

by Fred Pennic 01/05/2022 Leave a Comment

Protai Nabs $8M for AI-Powered Drug Discovery Platform

What You Should Know: - Protai, a Tel Aviv, Israel-based AI-powered drug discovery startup, today announced its emergence from stealth, along with an $8 million seed financing round co-led by Grove Ventures and Pitango HealthTech. - Protai empowers drug discovery with proteomics and artificial intelligence to unlock new layers of biological insights and to combat complex diseases. Proteomics-based Platform for Faster and More Accurate Drug Discovery Despite the significant
Read More

  • Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 61
  • Go to page 62
  • Go to page 63
  • Go to page 64
  • Go to page 65
  • Interim pages omitted …
  • Go to page 86
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Moving Beyond EHRs: What Lies Ahead for Healthcare Digitization?

AI Agents vs. Chatbots: Understanding Agentic AI’s Role in Healthcare

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

Healthcare's Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Healthcare’s Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |